Zevra Therapeutics Inc (ZVRA) — Titan Protect Analysis

ZVRA

Zevra Therapeutics Inc

Healthcare · ·

$10.61

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$649M

Total market value of the company

Trailing P/E

5.46

Very cheap relative to earnings

Forward P/E

5.73

Based on estimated future earnings — lower means cheaper

Rev Growth

+77.5%

Year-over-year revenue change

Profit Margin

101.6%

How much profit the company keeps from each dollar of revenue

ROE

100.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$24.00

+126% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 9 analysts covering this stock

About Zevra Therapeutics Inc

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational p

https://www.zevra.com

Country: United States Employees: 61 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.988

Good returns relative to risk taken

Kelly Fraction

0.0563

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.210

Returns exceed worst-case losses — strong risk profile

Annual Return

52.6%

Historical annualised return based on price data

Max Drawdown

-43.5%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.88

Less volatile than the market — more defensive

52W High

$13.16

19% below the year high

52W Low

$7.16

48% above the year low

Avg Volume

1,440,277

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$2.01

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.56

Moderate leverage — manageable

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

86.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

24.4%

Profit from core operations before interest and tax

Free Cash Flow

$26M

Positive — the business generates more cash than it spends

Revenue (TTM)

$122M

Total revenue over the last 12 months

Net Income

$117M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$26.00

Target Median

$24.00

Target Low

$18.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go